What is Orforglipron?
Orforglipron (LY3502970) is a non-peptide, small-molecule oral GLP-1 receptor agonist developed by Eli Lilly. Unlike all current GLP-1 agonists which are peptide-based and require injection, orforglipron is a small molecule that can be taken as a daily oral pill.
Why This Matters for Research
Current GLP-1 agonists like semaglutide and tirzepatide are peptides requiring subcutaneous injection. Oral semaglutide (Rybelsus) exists but uses a specialized absorption enhancer (SNAC) with strict fasting requirements. Orforglipron, being a non-peptide molecule, doesn’t face these bioavailability challenges.
Phase 2 Results
Phase 2 trials demonstrated dose-dependent metabolic improvements comparable to injectable GLP-1 agonists. The oral small-molecule approach could dramatically expand the research applications and accessibility of GLP-1 receptor modulation.
Small Molecule vs Peptide
The key distinction: peptide GLP-1 agonists (semaglutide, tirzepatide) are large molecules that require injection. Orforglipron is a small molecule (<500 Da) with oral bioavailability. This opens new research directions in oral GLP-1 pharmacology, pharmacokinetics, and CNS penetration studies.
For research and educational purposes only. Catalog | COAs
Related Articles
All products are sold strictly for research purposes only. Not for human consumption.